Giuseppe
Emeritus
[Source: PLoS ONE, full page: (LINK). Abstract, edited.]
-------
Avirulent Marek?s Disease Virus Type 1 Strain 814 Vectored Vaccine Expressing Avian Influenza (AI) Virus H5 Haemagglutinin Induced Better Protection Than Turkey Herpesvirus Vectored AI Vaccine
Hongyu Cui, Hongbo Gao, Xianlan Cui, Yan Zhao, Xingming Shi, Qiaoling Li, Shuai Yan, Ming Gao, Mei Wang, Changjun Liu, Yunfeng Wang
Affiliation: [Full list on source page.]
Abstract
Background
Herpesvirus of turkey (HVT) as a vector to express the haemagglutinin (HA) of avian influenza virus (AIV) H5 was developed and its protection against lethal Marek?s disease virus (MDV) and highly pathogenic AIV (HPAIV) challenges was evaluated previously. It is well-known that avirulemt MDV type 1 vaccines are more effective than HVT in prevention of lethal MDV infection. To further increase protective efficacy against HPAIV and lethal MDV, a recombinant MDV type 1 strain 814 was developed to express HA gene of HPAIV H5N1.
Methodology/Principal Findings
A recombinant MDV-1 strain 814 expressing HA gene of HPAIV H5N1 virus A/goose/Guangdong/3/96 at the US2 site (rMDV-HA) was developed under the control of a human CMV immediate-early promoter. The HA expression in the rMDV-HA was tested by immunofluorescence and Western blot analyses, and in vitro and in vivo growth properties of rMDV-HA were also analyzed. Furthermore, we evaluated and compared the protective immunity of rMDV-HA and previously constructed rHVT-HA against HPAIV and lethal MDV. Vaccination of chickens with rMDV-HA induced 80% protection against HPAIV, which was better than the protection rate by rHVT-HA (66.7%). In the animal study with MDV challenge, chickens immunized with rMDV-HA were completely protected against virulent MDV strain J-1 whereas rHVT-HA only induced 80% protection with the same challenge dose.
Conclusions/Significance
The rMDV-HA vaccine was more effective than rHVT-HA vaccine for protection against lethal MDV and HPAIV challenges. Therefore, avirulent MDV type 1 vaccine is a better vector than HVT for development of a recombinant live virus vaccine against virulent MDV and HPAIV in poultry.
Citation: Cui H, Gao H, Cui X, Zhao Y, Shi X, et al. (2013) Avirulent Marek?s Disease Virus Type 1 Strain 814 Vectored Vaccine Expressing Avian Influenza (AI) Virus H5 Haemagglutinin Induced Better Protection Than Turkey Herpesvirus Vectored AI Vaccine. PLoS ONE 8(1): e53340. doi:10.1371/journal.pone.0053340
Editor: Odir A. Dellagostin, Federal University of Pelotas, Brazil
Received: August 5, 2012; Accepted: November 27, 2012; Published: January 3, 2013
Copyright: ? 2013 Cui et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by a grant from the State Key Laboratory of Veterinary Biotechnology as Basic Research Programs of China (SKLVBP201212) and the Basic Scientific Research Operation Cost of State-leveled Public Welfare Scientific Research Courtyard (0302012009). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: yfwang@hvri.ac.cn
# These authors contributed equally to this work.
-Hongyu Cui, Hongbo Gao, Xianlan Cui, Yan Zhao, Xingming Shi, Qiaoling Li, Shuai Yan, Ming Gao, Mei Wang, Changjun Liu, Yunfeng Wang
Affiliation: [Full list on source page.]
Abstract
Background
Herpesvirus of turkey (HVT) as a vector to express the haemagglutinin (HA) of avian influenza virus (AIV) H5 was developed and its protection against lethal Marek?s disease virus (MDV) and highly pathogenic AIV (HPAIV) challenges was evaluated previously. It is well-known that avirulemt MDV type 1 vaccines are more effective than HVT in prevention of lethal MDV infection. To further increase protective efficacy against HPAIV and lethal MDV, a recombinant MDV type 1 strain 814 was developed to express HA gene of HPAIV H5N1.
Methodology/Principal Findings
A recombinant MDV-1 strain 814 expressing HA gene of HPAIV H5N1 virus A/goose/Guangdong/3/96 at the US2 site (rMDV-HA) was developed under the control of a human CMV immediate-early promoter. The HA expression in the rMDV-HA was tested by immunofluorescence and Western blot analyses, and in vitro and in vivo growth properties of rMDV-HA were also analyzed. Furthermore, we evaluated and compared the protective immunity of rMDV-HA and previously constructed rHVT-HA against HPAIV and lethal MDV. Vaccination of chickens with rMDV-HA induced 80% protection against HPAIV, which was better than the protection rate by rHVT-HA (66.7%). In the animal study with MDV challenge, chickens immunized with rMDV-HA were completely protected against virulent MDV strain J-1 whereas rHVT-HA only induced 80% protection with the same challenge dose.
Conclusions/Significance
The rMDV-HA vaccine was more effective than rHVT-HA vaccine for protection against lethal MDV and HPAIV challenges. Therefore, avirulent MDV type 1 vaccine is a better vector than HVT for development of a recombinant live virus vaccine against virulent MDV and HPAIV in poultry.
Citation: Cui H, Gao H, Cui X, Zhao Y, Shi X, et al. (2013) Avirulent Marek?s Disease Virus Type 1 Strain 814 Vectored Vaccine Expressing Avian Influenza (AI) Virus H5 Haemagglutinin Induced Better Protection Than Turkey Herpesvirus Vectored AI Vaccine. PLoS ONE 8(1): e53340. doi:10.1371/journal.pone.0053340
Editor: Odir A. Dellagostin, Federal University of Pelotas, Brazil
Received: August 5, 2012; Accepted: November 27, 2012; Published: January 3, 2013
Copyright: ? 2013 Cui et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by a grant from the State Key Laboratory of Veterinary Biotechnology as Basic Research Programs of China (SKLVBP201212) and the Basic Scientific Research Operation Cost of State-leveled Public Welfare Scientific Research Courtyard (0302012009). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: yfwang@hvri.ac.cn
# These authors contributed equally to this work.
-------